Biocon Biologics outlicenses two biosimilar assets to Yoshindo for commercialisation in Japan
bUstekinumab and bDenosumab to address market opportunity of approximately $700 million
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.